Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

Shares of bluebird bio (NASDAQ:BLUE) continued their downward descent Monday in the wake of news that the company has agreed to be taken private by Carlyle Group (NASDAQ:CG) and SK Capital ...

bluebird bio (NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the ...

Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...